Videos about peptides and SARMs that many people watch, next to what the studies say. We do not embed players and we do not repeat doses. Summaries are based on the title, description and chapters, because we cannot read the transcripts. A link to a video is not a recommendation.
Two pain medicine specialists go through the studies on BPC-157, TB-500, MOTS-c and GHK-Cu, the risk of contaminated products bought online, including heavy metals, and why a doctor should assess you first.
A clip from the podcast of a doctor who works on health in older age. The title sums up the conclusion: great marketing, not great science. The full episode also covers safety and grey-market peptides.
An orthopaedic shoulder surgeon goes through what studies say about BPC-157 for shoulder injuries. The description advertises paid consultations and his own guide.
The description has ads
A fertility doctor covers NAD+ drips marketed for fertility. She says the excitement rests mainly on animal studies, human data are thin and not peer-reviewed, and recalls a young woman who died after such a drip at a med spa.
A urologist who works on men's health goes through the studies on popular SARMs, MK-677 and cardarine: muscle gain, lower testosterone, the liver, cholesterol, fertility and false labels. According to the description, every SARM gets the lowest rating at the end.
A dermatologist reacts to videos of people taking melanotan 2: nausea, flushing and new moles that appeared within days. He goes through case reports of melanoma and whether the spray is any less risky than injections.
The description has ads
A dermatologist goes through the studies on GHK-Cu for skin, hair and wound healing. She explains how creams differ from injections and why injections are a concern: no approval for cosmetic use, few studies in people and uncertain product content.
The description has ads
A urologist who works on men's health covers MK-677 in a short video: strong hunger, water retention, higher blood sugar and a weaker response to insulin. He points out it is still being studied, has no FDA approval, and black-market products may be contaminated.
A lecture by a scientist who studies metabolism. He stresses that hopes for a longer life from rapamycin rest mainly on animal studies, and that in older people more muscle and protein go with a longer life.
The description has ads
A doctor covers hCG in men: how bodybuilders and men on testosterone treatment use it, new research on fertility, and side effects he says should be taken seriously. The video is from 2019.
A doctor who treats men with testosterone compares sermorelin and MK-677, which raise growth hormone in different ways. He talks about side effects he has seen in patients and his concerns about long-term use, including cancer risk with high IGF-1. The video is from 2019.
The same doctor covers growth hormone: effects on fat and muscle, medical uses, effects on blood sugar and the heart, carpal tunnel syndrome, cancer concerns and fakes. He stresses that long-term safety data are missing.
A report by Australia's ABC. Dermatologists say they are seeing patients who suddenly developed new, unusual and possibly dangerous moles while using melanotan 2. They advise anyone who used it to get a skin check.
A short news item from 2024: the FDA is looking into reports of hair loss and suicidal thoughts in people taking Ozempic, Wegovy and Mounjaro.
A short report from 2023: a Banner Health doctor talks about the side effects of Ozempic and Wegovy that they see more often since people started taking them for weight loss.
A coach responds to the Nippard video. According to the chapters in the description, he covers GLP-1 medicines using a client as an example, then BPC-157 and TB-500, the risk of products without quality control, and why to be sceptical of the claims.
The description has ads
A short video in which the author rates popular peptides on a scale from S to F. His ratings are an opinion on whether something is worth taking. Our grades from A to E only say how strong the studies are. The comparison below is based on the video description.
| The video | Their rating | Our grade |
|---|---|---|
| BPC-157 Better healing was seen in rats, and about 30 people have been studied. The stories are convincing, but most injuries heal on their own, so it is hard to tell whether BPC-157 did it. We agree on the conclusion. Ours is a D, because the results on healing come from animal studies. | low C | DRecovery and injury |
| Epitalon Extended life only in flies, mice and rats. No reliable studies in people, and where the products come from is uncertain. | F | DLonger life |
| MOTS-c Extended life only in animals. No reliable studies in people. | F | DLonger life |
| NAD+ Studies in people are very weak. The author points out that NAD+ is not a peptide. | D | ELonger life |
| Retatrutide Leads to even more weight loss, but is not approved in the US yet. The difference comes from what we grade. Large studies with random groups showed weight loss, hence the A. That the medicine is not approved is covered in the legal part. | B | AFat loss |
| Semaglutide Works for weight loss, but without strength training and protein you lose muscle. Nausea and diarrhoea are common. He says it suits people with overweight when a doctor prescribes it. | A | AFat loss |
| Tirzepatide Reduces hunger even more and leads to more weight loss than semaglutide. | A | AFat loss |
A bodybuilder with a biochemistry degree goes through peptides for weight loss, injury healing and longevity: what works, what the risks are and where studies are missing. The description lists his sources, mostly large studies of semaglutide and tirzepatide.
The description has ads
Commentary on how melanotan 2 injections became a TikTok trend. According to the chapters: side effects, the case of a man whose skin colour changed a lot after six months, addiction and body image problems, and "tanmaxxing" culture.
The author describes her sixth week on retatrutide: weight, side effects and appetite. She notes herself that it is a medicine still in trials and that she recommends nothing.
One person, no comparison group, and nobody knows what was in the product.
A nurse practitioner describes a year on prescribed tirzepatide: 55 lb lost and 52 things that surprised her. It is one person's account of taking the medicine legally.
One person, no comparison group, and nobody knows what was in the product.
The description has ads
A soft tissue therapist, who says he is not a doctor, takes BPC-157 for 30 days and describes his recovery and training. He stresses himself that studies in people are few.
One person, no comparison group, and nobody knows what was in the product.
The author took retatrutide outside of trials for 6 months and then stopped. He says he lost 25 lb, of which 10 lb was muscle according to a body scan (DEXA), and describes a reaction with a heartburn medicine that he says nearly put him in hospital.
One person, no comparison group, and nobody knows what was in the product.
The video talks about doses or buying. We do not repeat them.
Thumbnails are shown as a quotation for the purpose of this review. We check every few weeks that the videos are still public.
